

Synthesis and characterization of some new thieno[2,3-*b*]pyridines, thieno[2,3-*c*][2,7]naphthyridinones and pyrazolo[3,4-*c*][2,7]naphthyridinones with expected biological activity

Safiyah A. H. Al-Waleedy,^{a,b} Osama Younis,^c Shams H. Abdel-Hafez,^d and Etify A. Bakhite^{a*}

^aDepartment of Chemistry, Faculty of Science, Assiut University, Assiut, Egypt. ^bDepartment of Chemistry, Faculty of Science, Taiz University, Taiz, Yemen. ^cChemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt

^dDepartment of Chemistry, College of Science, Taif University, Taif 21944, Saudi Arabia
Email: etify@aun.edu.eg


Received 04-25-2024

Accepted 05-23-2024

Published on line 06-03-2024

Abstract

Ethyl 5-cyano-1,6-dihydro-2-methyl-4-styryl-6-thioxonicotinate, its piperidinium pyridine-6-thiolate and 3-acetyl-5-cyano-1,6-dihydro-2-methyl-4-styryl-6-thioxopyridine were used as starting materials for synthesizing novel series of *S*-substituted methylthiopyridine-5-carbonitriles and thieno[2,3-*b*]pyridines with expected biological activity. Also, some novel thieno[2,3-*c*][2,7]naphthyridinones were synthesized. Moreover, 1,7-diamino-8,9-dihydro-5-methyl-8-phenyl-3*H*-pyrazolo[3,4-*c*][2,7]naphthyridine-6(7*H*)-one was synthesized by heating ethyl 5-cyano-1,6-dihydro-2-methyl-4-styryl-6-thioxonicotinate with hydrazine hydrate 99% under neat conditions. The obtained promising aminopyrazolo[3,4-*c*][2,7]naphthyridine-6(7*H*)-one was used as a precursor to get other novel derivatives with expected biological and medicinal importance. Structures of all new compounds were elucidated by elemental and spectral analysis.



Keywords: Pyridines; thieno[2,3-*b*]pyridines; thienonaphthyridinones; pyrazolo[3,4-*c*][2,7]naphthyridines

Cite as *Arkivoc* 2024 (8) 202412212

DOI: <https://doi.org/10.24820/ark.5550190.p012.212>

Page 1 of 16

©AUTHOR(S)

Introduction

Thienopyridines have gained substantial consideration from researchers due to their high therapeutic values.¹⁻⁵ Thieno[2,3-*c*]pyridine nucleus shared in some approved drugs e.g. ticlopidine, clopidogrel and prasugrel (P2Y₁₂) Receptor blocker platelet aggregation inhibitors in the peripheral vascular, coronary artery and cerebrovascular diseases.¹ The research on the isomeric thieno[2,3-*b*]pyridines have been showing similar progress as well. A large number of biologically active compounds have been synthesized with the fused thieno[2,3-*b*]pyridine structural moiety as given in Figure 1. For instance, the plain thieno[2,3-*b*]pyridine scaffold that is mainly substituted at C2,3 and/or C4,6 has shown stimulatory activity against alkaline phosphatase (see compound **I** which is a potential drug candidate in the treatment of osteoporosis) (Figure 1).²

On the other hand, closely related 2,3-disubstituted thieno[2,3-*b*]pyridines **II**, **III** and **IVa** (Figure 1) displayed potent inhibition of rat urea transporter (UT-B),³ I κ B-kinase,⁴ and LIM domain kinase 1 (LIMK1)⁵ suggesting that these derivatives may act as a diuretic, potential antiproliferative or immunoprotective and antimetastatic agents, respectively. Furthermore, it is noticeable that the LIMK1 inhibitory activity has been amenable to a 4-fold increase as a result of extra-fusion of the plain thieno[2,3-*b*]pyridine scaffold with pyrimidine ring without any other structural modifications (see compounds **IVa,b**, Figure 1).⁵





Figure 1. Selected examples of promising thieno[2,3-*b*]pyridine drug candidates targeting various biological receptors and showing a wide diversity of biological activities.

Naphthyridine derivatives are reported to possess anticancer,^{6,7} antimalarial,⁸ anti-inflammatory,^{9,10} antiallergic,¹¹ and antiprotozoal¹² activity as well as inhibitory activity against bacterial topoisomerase,¹³ human acetylcholinesterase at as picomolar level,¹⁴ fibroblast activation protein,¹⁵ and HIV-1 integrase.¹⁶ 2,7-Naphthyridine moiety is found in a number of biologically important alkaloids^{17,18} such as meridine¹⁹ and PKD-1 inhibitor.²⁰

Encouraged by the above findings and as a continuation of our ongoing work on exploration the synthetic utility of ethyl 5-cyano-2-methyl-4-styryl-6-thioxo-1,6-dihydropyridine-3-carboxylate (**2a**),²¹⁻²² we reported herein some reactions of this compound and its 5-ethanone analogue **2b** with various reagents hoping to get new sulfanylpyridines, thieno[2,3-*b*]pyridines, thieno[2,3-*c*][2,7]naphthyridinones and pyrazolo[3,4-*c*][2,7]naphthyridinones with expected biological activity.


Results and Discussion

The key compounds, ethyl 5-cyano-1,6-dihydro-2-methyl-4-styryl-6-thioxonicotinate (**2a**)^{21,22} and 3-acetyl-5-cyano-1,6-dihydro-2-methyl-4-styryl-6-thioxopyridine (**2b**)²³ were synthesized according to the methods described before. The acidity of pyridinethiol **2a** was checked by its reaction with piperidine, wherein the piperidinium pyridine-6-thiolate **3** was obtained (Scheme 1).²⁴



Scheme 1. Synthesis of starting materials **2a,b** and **3**.

Reaction of piperidinium thiolate **3** with some alkylating agents namely; iodoethane, ω -bromoacetophenone, chloroacetonitrile, ethyl bromoacetate or 2-chloroacetamide by stirring in ethanol for one hour gave sulfanylpyridines **4**, **5**, **6**, **7** and **8** in nearly quantitative yields (Scheme 2).




Scheme 2. Synthesis of compounds **4-8**.

IR spectra of **4-8** exhibited two absorption bands at 2223- 2218 cm^{-1} characteristic for (CN) and 1725-1702 cm^{-1} for (CO, ester) besides other bands corresponding to the other functional groups of each. ^1H NMR of **4** showed two signals due to SCH_2CH_3 group. ^1H NMR of **5-8** displayed a singlet at δ 4.02-5.11 for SCH_2 group.

Intramolecular Thorpe-Ziegler cyclization of the latter compounds (**5**, **6**, **7** and **8**) into the corresponding thienopyridines **9**, **10**, **11** and **12** needs different basic conditions. Thus, heating ketone **5** in ethanol for 30 mins, in the absence of any catalyst, furnished thienopyridine **9**. On refluxing of acetonitrile derivative **6** in ethanol containing a catalytic amount of AcONa for 30 mins., the expected thienopyridine **10** was isolated. Cyclization of ester **7** into its isomer **11** needs heating in ethanol in the presence of a catalytic amount of AcONa for 2 hours. In contrast, cyclization of acetamide **8** into thienopyridine **12** was achieved when anhydrous sodium carbonate was used as a catalyst in boiling ethanol (Scheme 3).


Thienopyridines **9**, **10**, **11** and **12** were also synthesized by independent methods. Thus, heating compound **2a** with ω -cyanoacetophenone, in ethanol in the presence of an equimolar quantity of sodium acetate for 30 mins. gave thienopyridine **9**. Refluxing of compound **2a** with chloroacetonitrile in ethanol containing a slightly excess quantity of AcONa for 30 mins. led to the formation of thienopyridine **10**. Heating **2a** with ethyl bromoacetate in ethanol containing a slightly excess amount of AcONa for 2 hours furnished *o*-aminoester **11**. Compound **12** was obtained by reacting **2a** with 2-chloroacetamide in boiling ethanol in the presence of a slightly excess molar quantity of anhydrous Na_2CO_3 (Scheme 3).



Scheme 3. Synthesis of compounds 9-12.


By taking the above reactions in our consideration, we can conclude that the order of activity of methylene groups in compounds 5, 6, 7 and 8 towards intramolecular Thorpe-Ziegler cyclization is: $-\text{CH}_2\text{COPh} > -\text{CH}_2\text{CN} > -\text{CH}_2\text{CO}_2\text{Et} > -\text{CH}_2\text{CONH}_2$. The above fact based on the following findings: (i) cyclization of 5 into 9 takes place in boiling ethanol without catalyst, (ii) cyclization of 6 or 7 into 10 or 11 requires boiling in ethanol in the presence of AcONa, as a mild basic catalyst, for 30 mins. or 2 hours respectively and (iii) cyclization of 8 into 12 was achieved by boiling in ethanol containing a catalytic quantity of Na_2CO_3 as a moderate basic catalyst.

In a similar manner, reaction of ethanone analogue **2b** with ω -bromoacetophenone, chloroacetonitrile, ethyl bromoacetate or 2-chloroacetamide by heating in ethanol containing anhydrous Na_2CO_3 , gave poly functionally substituted thieno[2,3-*b*]pyridines **13**, **14**, **15** and **16** (Scheme 4).




Scheme 4. Synthesis of thieno[2,3-*b*]pyridines **13-16**.

Heating of **7** or **11** with an excess molar amount of hydrazine hydrate 99% furnished diaminothienopyridinecarbohydrazide (**17**) (Scheme 5).




Scheme 5. Synthesis of compound **17**.

Reaction of cyclic ester **11** with 2,5-dimethoxytetrahydrofuran is reported to give the pyrrolyl derivative **18**.²² Fusion of **18** with an excess molar amount of hydrazine hydrate 99% afforded aminopyrrolyl-thienonaphthyridinecarbohydrazide **19**. The latter compound **19** was condensed with two molar ratios of 4-methoxybenzaldehyde to give bis(4-methoxybenzylidene) derivative **20** (Scheme 6).



Scheme 6. Synthesis of compounds **19** and **20**.


The above formation of 2,7-naphthyridines promoted us to check the action of hydrazine hydrate on the starting compound **2a** under the same (above) conditions. Thus, heating of **2a** with an extra amount of hydrazine hydrate at 100 °C led to the formation of a colorless crystalline solid with melting point 238 °C in excellent yield. This structure of this product was assigned as diaminopyrazolonaphthyridinone **24** among four proposed structures **21-24** with the same molecular formula, C₁₆H₁₆N₆O (Scheme 7).



Scheme 7. Synthesis of diaminopyrazolonaphthyridinone **24**.

The diaminopyrazolonaphthyridinone **24** was utilized as a key intermediate for building other novel pyrazolonaphthyridinones. Thus, condensation of **24** with two molar ratios of benzaldehyde or its derivatives by heating in ethanol gave the promising dibenzylidenes **25a-f** in excellent yields. Reaction of **20** with two molar ratios of acetylacetone by refluxing in ethanol furnished dihydropyrimidopyrazolonaphthyridinone **26** which exists predominantly in the enol form (Scheme 8).

IR and ^1H NMR spectra of **25a-f** and **26** proved the disappearance of the two amino groups and appearance of two azomethine groups.



Scheme 8. Synthesis of pyrazolonaphthyridinones **25a-f** and **26**.

All new compounds were characterized by elemental and spectral analyses (*cf.* Experimental Section and Figures S1-S51).

Conclusions

We have successfully used the easily available ethyl 5-cyano-2-methyl-4-styryl-6-thioxo-1,6-dihydropyridine-3-carboxylate and 3-acetyl-5-cyano-2-methyl-4-styryl-6-thioxo-1,6-dihydropyridine as starting materials in the synthesis of novel series of functionally substituted methylsulfanylpyridines, thieno[2,3-*b*]pyridines, thieno[2,3-*c*][2,7]naphthyridinones and pyrazolo[3,4-*c*][2,7]naphthyridinones with expected biological activity owing to incorporation of several pharmacophores into their structures. These promising compounds were obtained in a very pure state with excellent yields.

Experimental Section

General. Melting points were determined on a Gallen-kamp apparatus. IR spectra were recorded on a Shimadzu 470 IR-spectrophotometer (KBr; ν_{\max} in cm^{-1}). ^1H NMR spectra were recorded on a Bruker 400 MHz spectrometer using CDCl_3 or $\text{DMSO}-d_6$ as a solvent and tetramethylsilane (TMS) as internal reference. ^{13}C NMR and Dept 135 spectra were recorded on a Bruker 100 MHz spectrometer using CDCl_3 or $\text{DMSO}-d_6$ as a solvent and tetramethylsilane (TMS) as internal reference. Coupling constants (J values) are given in Hertz (Hz). Elemental analyses were performed on Perkin Elmer 2400 LS Series CHN/O analyzer. MS analyses were performed on a Thermo Scientific single quadrupole mass spectrometer Model: ISQ 7000.

Reaction of piperidinium thiolate **3** with iodoethane, ω -cyanoacetophenone, chloroacetonitrile; ethyl bromoacetate or 2-chloroacetamide; Formation of sulfanylpyridines **4**, **5**, **6**, **7** and **8**; general procedure

Compound **3** (2.04 g, 0.005 mol) and iodoethane, ω -cyanoacetophenone, chloroacetonitrile; ethyl bromoacetate or 2-chloroacetamide (0.005 mol) in EtOH (35 mL) was stirred at 25 °C for one hour. The product that obtained was assigned as compound **4**, **5**, **6**, **7** or **8**, respectively.

Compound 4. Yield: 1.58 g (90%); mp 147-148 °C. IR: 2221 (CN); 1730 (CO). ^1H NMR: 7.05-7.55 (m, 7H: CH=CH & aryl-H's), 4.25-4.30 (q, 2H, OCH_2), 2.41 (s, 3H, CH_3), 1.24-1.27 (t, 3H, CH_3) ppm. Anal. Calcd. For $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2\text{S}$ (352.12): C, 68.16; H, 5.72; N, 7.95; S, 9.10%. Found: C, 68.35; H, 5.62; N, 8.13; S, 8.92%.

Compound 5. Yield: 2.10 g (95%); mp 122-123 °C. IR: 3057 (CH, arom.); 2974, 2910 (CH, aliph.); 2223 (CN); 1725 (CO, ester); 1682 (CO, nonconjugated ketone). ^1H NMR: 7.22-7.78 (m, 11H, CH=C & aryl-H's), 6.87-6.89 (d, 1H, C=CH), 5.11 (s, 2H, SCH_2), 4.31-4.35 (q, 2H, OCH_2), 2.66 (s, 3H, CH_3), 1.24-1.27 (t, 3H, CH_3) ppm. Anal. Calcd. For $\text{C}_{26}\text{H}_{22}\text{N}_2\text{O}_3\text{S}$ (442.13): C, 70.57; H, 5.01; N, 6.33; S, 7.24%. Found: C, 70.28; H, 5.17; N, 6.41; S, 6.98 %.

Compound 6. Yield: 1.70 g (94%); mp 184-186 °C. IR: 2980, 2932, 2902 (CH, aliph.); 2247 (CN, nonconjugated); 2220 (CN, conjugated); 1718 (CO, ester). ^1H NMR: 6.66-7.70 (m, 7H: CH=CH & aryl-H's), 5.02 (s, 2H, SCH_2), 4.09-4.13 (q, 2H, OCH_2), 2.58 (s, 3H, CH_3), 1.25-1.27 (t, 3H, CH_3) ppm. Anal. Calcd. For $\text{C}_{20}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$ (363.10): C, 66.10; H, 4.71; N, 11.56; S, 8.82%. Found: C, 65.93; H, 5.06; N, 11.42; S, 9.06%.

Compound 7. Yield: 1.98 g (97%); mp 70-71 °C. IR: 2982 (CH, aliph.); 2219 (CN); 1748 (CO, nonconjugated ester); 1724 (CO, conjugated ester). ^1H NMR: 6.60-7.63 (m, 7H: CH=CH & aryl-H's), 4.16-4.37 (m, 6H: OCH_2 & SCH_2), 2.52 (s, 3H, CH_3), 1.21-1.27 (2 t, 6H: two CH_3) ppm. Anal. Calcd. For $\text{C}_{22}\text{H}_{22}\text{N}_2\text{O}_4\text{S}$ (410.13): C, 64.37; H, 5.40; N, 6.82; S, 7.81%. Found: C, 64.12; H, 5.34; N, 6.91; S, 8.07%.

Compound 8. Yield: 1.69 g (89%); mp 171-172 °C. IR: 3304, 3268, 3199 (NH_2); 2980, 2927 (CH, aliph.); 2219 (CN); 1702 (CO, ester); 1670 (CO, amide). ^1H NMR: 7.23-7.68 (m, 9H: NH_2 , CH=CH & aryl-H's), 4.33-4.37 (q, 2H, OCH_2), 4.02 (s, 2H, SCH_2), 2.55 (s, 3H, CH_3), 1.22-1.25 (t, 3H, CH_3) ppm. ^{13}C NMR & Dept 135: 169.10, 169.03, 166.68, 163.29, 158.85, 148.23, 139.69 (CH=C), 135.48, 135.39, 130.17 (CH), 127.83 (CH), 123.68 (CH), 121.47 (C=CH), 115.39, 102.30, 62.42 (OCH_2), 34.44 (SCH_2), 23.94 (CH_3), 14.35 (CH_3) ppm. Anal. Calcd. For $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_3\text{S}$ (381.11): C, 62.98; H, 5.02; N, 11.02; S, 8.40%. Found: C, 62.77; H, 5.09; N, 11.13; S, 8.11%.

3-Amino-2-benzoyl-5-ethoxycarbonyl-6-methyl-4-styrylthieno[2,3-*b*] pyridine (**9**)

(A) Compound **5** (0.88 g, 0.002 mol) in EtOH (30 mL) was refluxed for 30 mins. The product was recrystallized from EtOH to give orange needles of compound **9**. Yield: 2.01 g (91%); mp 284-285 °C. IR: 3476, 3270 (NH_2), 1709 (CO). ^1H NMR: 6.66-7.85 (m, 13H: NH_2 , CH=C & aryl-H's), 6.89-6.92 (d, 1H, C=CH), 4.30-4.34 (q, 2H, OCH_2), 2.67 (s, 3H, CH_3), 1.25-1.28 (t, 3H, CH_3) ppm. ^{13}C NMR & Dept 135: 190.58, 168.02, 162.76, 157.29, 150.96, 142.58, 140.77, 138.51 (C=CH), 135.05, 131.28 (CH), 129.52 (CH), 129.14(CH), 129.03 (CH), 128.37 (CH), 128.03 (CH), 127.87(CH), 126.98(CH), 125.89, 120.82 (CH=C), 119.62, 105.78, 61.83 (OCH_2), 23.48 (CH_3), 14.24 (CH_3)

ppm. Anal. Calcd. For $C_{26}H_{22}N_2O_3S$ (442.13): C, 70.57; H, 5.01; N, 6.33; S, 7.24%. Found: C, 70.67; H, 5.24; N, 6.13; S, 7.15%.

(B) A suspension of **2a** (0.64 g, 0.002 mol), phenacyl bromide (0.40 g, 0.002 mol) and $AcONa \cdot 3H_2O$ (0.28 g, 0.002 mol) in EtOH (30 mL) was refluxed for 30 mins. The product upon recrystallization gave orange needles of **9**; yield: 0.76 g (86%).

Ethyl 3-amino-2-cyano-6-methyl-4-styrylthieno[2,3-*b*]pyridine-2-carboxylate (**10**)

(A) Compound **6** (0.36 g, 0.001 mol) and $AcONa \cdot 3H_2O$ (0.05 g) in EtOH (25 mL) were refluxed for 30 mins. The product was recrystallized from EtOH to afford canary needles of **10**. Yield: 0.33 g (91%); mp 257-258 °C. IR: 3470, 3335, 3226 (NH_2); 2975, 2934 (CH, aliph.); 2201 (CN); 1731 (CO, ester). 1H NMR: 7.38-7.51 (m, 6H: CH=C & aryl-H's), 6.84-6.87 (d, 1H, C=CH), 6.39 (s, 2H, NH_2), 4.31-4.35 (q, 2H, OCH_2), 2.66 (s, 3H, CH_3), 1.26-1.28 (t, 3H, CH_3) ppm. ^{13}C NMR: 167.75, 161.41, 156.77, 149.70, 141.43, 138.93, 134.90, 129.62, 129.16, 129.02, 126.98, 126.30, 120.33, 118.51, 114.77, 61.97, 23.30, 14.23 ppm. Anal. Calcd. For $C_{20}H_{17}N_3O_2S$ (363.10): C, 66.11; H, 4.72; N, 11.57; S, 8.83%. Found: 66.30; H, 4.80; N, 11.88; S, 8.65%.

(B) A ternary mixture of **2a** (0.64 g, 0.002 mol), chloroacetonitrile (0.002 mol) and $AcONa \cdot 3H_2O$ (0.38 g) in EtOH (35 mL) was refluxed for 30 mins. The product upon recrystallization from EtOH gave canary needles of **10**; yield: 0.60 g (83%).

3-Amino-2,5-diethoxycarbonyl-6-methyl-4-styrylthieno[2,3-*b*]pyridine (**11**)

(A) A suspension of **7** (2.05 g, 0.005 mol) and $AcONa \cdot 3H_2O$ (0.25 g) in EtOH (30 mL) was refluxed for for 2.5 h. The precipitated solid upon recrystallized from EtOH gave canary needles of compound **11**. Yield: 1.90 g (93%); mp 116-117°C. IR: 3491, 3349 (NH_2); 2982 (CH, aliph.); 1714 (CO); 1671 (CO). 1H NMR: 7.75-7.78 (d, 1H, CH=C), 7.65-7.66 (d, 2H, aryl-H's), 7.36-7.45 (m, 3H, aryl- H's), 6.79-.83 (d, 1H, C=CH), 6.61 (s, 2H, NH_2), 4.23-4.30 (m, 4H, 2 OCH_2), 2.57 (s, 3H, CH_3), 1.28-1.31 (t, 3H, CH_3), 1.15-1.18 (t, 3H, CH_3) ppm. ^{13}C NMR & Dept 135: 168.03, 164.87, 160.66, 156.26, 149.29, 142.94, 138.30 (CH), 135.88, 129.51(CH), 129.27 (CH), 127.73 (CH), 126.03, 121.87(CH), 120.57, 95.82, 61.97 (OCH_2), 60.77 (OCH_2), 23.27 (CH_3 at C-6), 14.83 (CH_3), 14.41 (CH_3) ppm. Anal. Calcd. For $C_{22}H_{22}N_2O_4S$ (410.13): C, 64.37; H, 5.40; N, 6.82; S, 7.81%. Found: C, 64.12; H, 5.34; N, 6.91; S, 7.96%.

(B) A mixture of **2a** (1.62 g, 0.005 mol), ethyl bromoacetate (0.55 ml, 0.005 mol) and $AcONa \cdot 3H_2O$ (0.95 g) in EtOH (50 mL) was refluxed for 3 h. The product was identical to that given above; yield: 1.70 g (83%).

3-Amino-5-ethoxycarbonyl-6-methyl-4-styrylthieno[2,3-*b*]pyridine-2-carboxamide(**12**)

(A) A mixture of **8** (0.76 g, 0.002 mol) and anhyd. Na_2CO_3 (0.25 g) in EtOH (30 mL) was refluxed for two hours. The solid that separated was recrystallized from methanol to give compound **12** as yellow needles. Yield: 0.71 g (94%); mp 276-277°C. IR: 3476, 3270 (NH_2), 1709 (CO). 1H NMR: 7.39-7.70 (m, 13H: NH_2 , CH=C & aryl-H's), 6.77-6.80 (d, 1H, C=CH), 2.52 (s, 3H, CH_3), 2.43 (s, 3H, CH_3) ppm. ^{13}C NMR and Dept 135: 205.31 (C=O), 189.58(C=O), 161.31, 156.49, 151.97, 142.18, 141.14, 140.21(CH), 135.86, 133.84, 131.74(CH), 129.74(CH), 129.28(CH), 129.01(CH), 128.02(CH), 127.81(CH), 121.68(CH), 120.08, 103.94, 32.82(CH_3), 23.45 (CH_3) ppm. Anal. Calcd. For $C_{20}H_{19}N_3O_3S$ (381.11): C, 62.98; H, 5.02; N, 11.02; S, 8.40%. Found: C, 62.68; H, 4.79; N, 11.22; S, 8.34%.

(B) A mixture of **2a** (0.64 g, 0.002 mol), 2-chloroacetamide (0.002 mol) and anhyd. Na_2CO_3 (0.25 g) in EtOH (30 mL) was refluxed for 2 hours. The solid that obtained was recrystallized from methanol to give **12**; yield: 0.69 g (91%).

Reaction of **2b** with ω -bromoacetophenone, chloroacetonitrile, ethyl bromoacetate and 2-chloroacetamide; Construction of thienopyridines **13**, **14**, **15** or **16**; general procedure

A mixture of **2b** (0.60 g, 0.002 mol), ω -bromoacetophenone, chloroacetonitrile, ethyl bromoacetate or 2-chloroacetamide (0.002 mol) in EtOH (30 mL) and anhyd. Na_2CO_3 (0.25 g) was refluxed for 3 hours. The separated solid was recrystallized from methanol to furnish canary crystals of **13**, **14**, **15** or **16**, respectively.

Compound 13. Yield: 0.80 g (97%); mp 289-290 °C. IR: 3476, 3270 (NH₂), 1709 (CO). ¹H NMR: 7.39-7.70 (m, 13H: NH₂, CH=C & aryl-H's), 6.77-6.80 (d, 1H, C=CH), 2.52 (s, 3H, CH₃), 2.43 (s, 3H, CH₃) ppm. ¹³C NMR and Dept 135: 205.31 (C=O), 189.58(C=O), 161.31, 156.49, 151.97, 142.18, 141.14, 140.21(CH), 135.86, 133.84, 131.74(CH), 129.74(CH), 129.28(CH), 129.01(CH), 128.02(CH), 127.81(CH), 121.68(CH), 120.08, 103.94, 32.82(CH₃), 23.45 (CH₃) ppm. Anal. Calcd. For C₂₅H₂₀N₂O₂S (412.12): C, 72.79; H, 4.89; N, 6.79; S, 7.24%. Found: C, 72.54; H, 4.70; N, 6.79; S, 6.98%.

Compound 14. Yield: 0.56 g (93%); mp 261-262°C. IR: 3472, 3345, 3230 (NH₂); 2978, 2932 (CH, aliph.); 2200 (CN); 1710 (CO). ¹H NMR: 7.82-7.85 (d, 1H, C=CH), 7.42-7.67 (m, 2H, aryl-H's), 7.38-7.40 (m, 3H, aryl-H's), 6.69-6.73 (d, 1H, CH=C), 6.47 (s, 2H, NH₂), 2.52 (s, 3H, CH₃), 2.42(s, 3H, CH₃) ppm. ¹³C NMR & Dept 135: 205.16 (C=O), 160.07(C≡N), 155.60, 151.67, 141.20, 140.20(CH), 135.85, 134.04, 129.69(CH), 129.28(CH), 127.89(CH), 121.60(CH), 119.37, 115.80, 32.80 (CH₃), 23.23 (CH₃) ppm. Anal. Calcd. For C₁₉H₁₅N₃OS (303.09): C, 68.45; H, 4.53; N, 12.60; S, 9.62%. Found: C, 68.73; H, 4.39; N, 12.42; S, 9.85%.

Compound 15. Yield: 0.70 g (92%); mp 128-129°C. IR: 3496, 3350 (NH₂); 2980 (CH, aliph.); 1705 (CO); 1672 (CO). ¹H NMR: 7.80-7.84 (d, 1H, CH=C), 7.65-7.67 (d, 2H, aryl-H's), 7.37-7.46 (m, 3H, aryl-H's), 6.71-6.75 (d, 1H, C=CH), 6.61 (s, 2H, NH₂), 4.26-4.30 (q, 2H, OCH₂), 2.50 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 1.28-1.31 (t, 3H, CH₃) ppm. ¹³C NMR and Dept 135: 205.43 (C=O), 164.94, 160.00, 155.33, 149.45 141.31, 139.86 (CH), 135.92, 133.63, 129.65(CH), 129.28(CH), 127.88 (CH), 121.88(CH), 120.59, 60.74 (OCH₂), 32.84(CH₃), 23.27 (CH₃), 14.84 (CH₃) ppm. Anal. Calcd. For C₂₁H₂₀N₂O₃S (380.12): C, 66.29; H, 5.30; N, 7.36; S, 8.43%. Found: C, 66.11; H, 5.21; N, 7.19; S, 8.33%.

Compound 16. Yield: 0.66 g (94%); mp 287-289 °C. IR: 3438, 3331, 3272, 3160 (2 NH₂); 2981 (CH, aliph.); 1703 (CO); 1660 (CO). ¹H NMR: 7.64-7.67 (d, 1H, CH=C), 7.29-7.45 (m, 7H: CONH₂ & aryl-H's), 6.77-6.81 (d, 1H, C=CH), 6.65 (s, 2H, NH₂), 2.52 (s, 3H, CH₃), 2.43 (s, 3H, CH₃) ppm. Anal. Calcd. For C₁₉H₁₇N₃O₂S (351.10): C, 64.94; H, 4.88; N, 11.96; S, 9.12%. Found: C, 65.12; H, 4.71; N, 11.82; S, 9.00%.

1,7-Diamino-5-methyl-6-oxo-8-phenyl-6,7,8,9-tetrahydrothieno[2,3-c][2,7]naphthyridine-2-carbohydrazide (17). A suspension of compound **7** or **11** (2.05 g, 0.005 mol) in hydrazine hydrate 99% (4 mL, 0.08 mol) was heated at 100 °C for 4 h. The product was recrystallized from dioxane to give **17** as yellowish white needles. Yield: 1.72 g (90%); mp 280-281°C. IR: 3464, 3403, 3327, 3296, 3204 (3 NH₂, NH); 3023 (CH, arom.); 2929 (CH, aliph.); 1640 (CO). ¹H NMR: δ 9.12 (s, 1H, NH), 7.25-7.28 (m, 2H, aryl-H's), 7.13-7.20 (m, 3H, aryl-H's), 6.75 (s, 2H, NH₂), 5.25 (s, 2H, NH₂), 5.10-5.11 (d, 1H, C⁸H, of cyclohexene ring), 4.43 (s, 2H, NH₂ of carbohydrazide), 3.94-4.08 (m, 2H, C⁹H₂ of cyclohexene ring), 2.90 (s, 3H, CH₃) ppm. Anal. Calcd. For C₁₈H₁₈N₆O₂S (382.12): C, 56.52; H, 4.74; N, 8.37; S, 7.24%. Found: C, 56.22; H, 4.79; N, 8.20; S, 6.98%.

7-Amino-5-methyl-6-oxo-8-phenyl-1-(1H-pyrrol-1-yl)-6,7,8,9-tetrahydrothieno[2,3-c][2,7]naphthyridine-2-carbohydrazide (19). It was synthesized by reaction of **18**²² with hydrazine hydrate 99% in a similar procedure given for compound **17**. Yield: 2.05 g (95%); mp 256-257°C. IR: 3400, 3298, 3208, 3117 (NH₂, NHNH₂), 3031 (CH, arom.), 1648 (2 CO). ¹H NMR: 8.37 (s, 1H, NH), 6.40-7.23 (m, 11H, aryl-H's & pyrrole-H's), 5.22 (s, 2H, NH₂), 4.85 (s, 1H, C⁸H of cyclohexene ring), 4.49 (s, 2H, NH₂ of carbohydrazide), 3.29 (m, 2H, C⁹H₂ of cyclohexene ring), 2.96 (s, 3H, CH₃) ppm. Anal. Calcd. For C₂₂H₂₀N₆O₂S (432.14): C, 61.10; H, 4.66; N, 19.43; S, 7.41%. Found: C, 60.87; H, 5.02; N, 19.21; S, 7.19%.

N'-(4-Methoxybenzylidene)-7-(4-methoxybenzylidene)amino)-5-methyl-6-oxo-8-phenyl-1-(1H-pyrrol-1-yl)-6,7,8,9-tetrahydrothieno[2,3-c][2,7]naphthyridine-2-carbohydrazide (20).

A mixture of **19** (0.86 g, 0.002 mol) and 4-mthoxybenzaldehyde (0.56 g, 0.004 mol) in EtOH (20 mL) was heated under reflux for 3 h. The solid that separated while hot was crystallized from dioxane to yield pale yellow crystals of compound **20**. Yield: 2.48 g (93%); mp 298-300 °C. IR: 3427, 3281, 3108, (NH₂, NH), 1651 (2 CO). ¹H NMR: 9.09 (s, 1H, CH, azomethine), 8.94 (s, 1H, NH), 8.55 (s, 1H, CH, azomethine), 6.40-8.20 (m, 17H: aryl-H's

& pyrrole-H's), 6.22 (s, 2H, NH₂), 3.97(s, 3H, OCH₃), 3.89 (s, 3H, OCH₃), 4.86 (s, 1H, C⁸H of cyclohexene ring), 3.28 (m, 2H, C⁹H₂ of cyclohexene ring), 2.93 (s, 3H, CH₃). Anal. Calcd. For C₃₈H₃₂N₆O₄S (668.22): C, 68.25; H, 4.82; N, 12.57; S, 4.79%. Found: C, 68.39; H, 5.08; N, 12.36; S, 4.51%.

1,7-Diamino-5-methyl-8-phenyl-8,9-dihydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-6(7H)-one (24). A suspension of compound **2a** (1.62 g, 0.005 mol) in hydrazine hydrate 99% (5 mL, 0.1 mol) was heated under reflux for 2 h. The precipitate that separated on cooling was recrystallized from EtOH to give compound **24**. Yield: 1.41 g (92%); mp 238-240 °C. IR: 3310, 3200, 3147 (NH₂, NH), 3031 (CH, arom.), 2925, 2819 (CH, aliph.), 1650 (CO), 1605 (CN). ¹H NMR: 12.08 (s, 1H, NH), 7.25-7.26 (m, 2H, aryl-H's), 7.16-7.20 (m, 3H, aryl-H's), 5.31 (s, 2H, NH₂), 5.05-5.11 (m, 3H: NH₂ and C⁸H of cyclohexene ring), 3.71-3.83 (m, 2H, C⁹H₂ of cyclohexene ring), 2.85 (s, 3H, CH₃). MS: *m/z* 308.26 (M⁺, 30%). Anal. Calcd. For C₁₆H₁₆N₆O (308.14): C, 62.32; H, 5.23; N, 27.26%. Found: C, 62.32; H, 5.23; N, 27.29%.

Condensation of 24 with aryl aldehydes; Formation of dibenzylidene derivatives 25a-f. A mixture of **24** (0.92 g, 0.003 mol) and appropriate aryl aldehyde (0.006 mol) in EtOH (20 mL) was refluxed for 3 h. The product that separated while hot was crystallized from dioxane to produce yellow needles of **25a-f**.

Compound 25a. Yield: 1.23 g (85%); mp 282-284 °C. IR: 3126 (NH); 3062, 3027 (CH, arom.); 2987, 2924, 2846 (CH, aliph.); 1663 (CO); 1605 (CN). ¹H NMR: δ 13.53 (s, 1H, NH), 9.13 (s, 1H, CH, azomethine), 8.53 (s, 1H, CH, azomethine), 8.08-8.10 (d, 2H, aryl-H's), 7.72-7.73 (d, 2H, Ar-H's), 7.61-7.62 (d, 3H, aryl-H's), 7.43-7.44 (d, 3H, Ar-H's), 7.21-7.26 (m, 4H, aryl-H's), 7.13-7.16 (m, 1H, Ar-H), 5.92-5.94 (d, 1H, C⁸H of cyclohexene ring), 4.37-4.42 (d, 1H, C⁹H of cyclohexene ring), 4.03-4.08 (dd, 1H, C⁹H of cyclohexene ring), 2.95 (s, 3H, CH₃) ppm. Anal. Calcd. For C₃₀H₂₄N₆O (484.20): C, 74.36; H, 4.99; N, 17.34%. Found: C, 74.18; H, 4.72; N, 17.61%.

Compound 25b. Yield: 1.32 g (81%); mp 320-322 °C. IR: 3150 (NH); 3129 (CH, arom.); 2930, 2837 (CH, aliph.); 1654 (=O). ¹H NMR: 13.46 (s, 1H, NH), 9.02 (s, 1H, CH, azomethine), 8.42 (s, 1H, CH, azomethine), 8.02-8.03 (d, 2H, Ar-H's), 7.66-7.67 (d, 2H, aryl-H's), 6.98-7.24 (m, 13H, aryl-H's), 5.86 (s, 1H, C⁸H of cyclohexene ring), 4.35-4.38 (d, 1H, C⁹H of cyclohexene ring), 4.00-4.03 (dd, 1H, C⁹H of cyclohexene ring), 3.87(s, 3H, OCH₃), 3.79 (s, 3H, OCH₃), 2.93 (s, 3H, CH₃) ppm. ¹³C NMR and Dept 135: 163.05, 161.46, 161.32, 161.00 (CH), 160.28, 152.26, 152.08, 149.35 (CH), 143.34, 139.37, 131.44 (CH), 129.44 (CH), 129.14 (CH), 128.95, 127.83 (CH), 127.52, 126.33 (CH), 118.37, 115.04 (CH), 114.73 (CH), 106.68, 58.22 (CH), 55.99 (OCH₃), 55.76 (OCH₃), 32.37 (CH₂), 26.89 (CH₃) ppm. Anal. Calcd. For C₃₂H₂₈N₆O₃ (544.22): C, 70.57; H, 5.18; N, 15.43%. Found: C, C, 70.81; H, 4.89; N, 15.15%.

Compound 25c. Yield: 1.37 g (88%); mp 354-356 °C. IR: 3104 (NH); 3064, 3026 (CH, arom.); 2923, 2807 (CH, aliph.); 1649 (CO); 1611 (CN). ¹H NMR: 13.82 (s, 1H, NH), 12.10 (s, 2H, two CH, azomethine), 8.30-8.59 m, 5H, aryl-H's), 7.96-8.01 (d, 2H, aryl-H's), 7.21-7.28 (m, 6H, aryl-H's), 5.93 (s, 1H, C⁸H of cyclohexene ring), 5.46 (s, 1H, C⁹H of cyclohexene ring), 4.02 (d, 1H, C⁹H of cyclohexene ring), 2.87 (s, 3H, CH₃) ppm. Anal. Calcd. For C₃₀H₂₂Cl₂N₆O (552.12): C, 65.11; H, 4.01; N, 15.19%. Found: C, 65.00; H, 3.95; N, 15.31%.

Compound 25d. Yield: 1.36 g (88%); mp 292-294 °C. IR: 3423 (OH); 3128 (NH); 1660 (CO); ¹H NMR: δ 13.69 (s, 1H, NH), 12.13 (s, 1H, OH), 11.93 (s, 1H, OH), 9.37-9.38 (s, 1H, CH, azomethine), 8.36 (s, 1H, CH, azomethine), 7.87-7.89 (d, 1H, aryl-H's), 7.50-7.52 (d, 1H, aryl-H), 7.39-7.40 (d, 1H, aryl-H), 7.27-7.28 (m, 3H, aryl-H's), 7.18 (br. s, 3H, aryl-H's), 7.05-7.08 (m, 2H, aryl-H's), 6.89-6.95 (m, 2H, aryl-H's), 6.15 (s, 1H, C⁸H of cyclohexene ring), 4.17 (s, 2H, C⁹H₂ of cyclohexene ring), 2.99 (s, 3H, CH₃) ppm. Anal. Calcd. For C₃₀H₂₄N₆O₃ (516.19): C, 69.76; H, 4.68; N, 16.27%. Found: C, 69.85; H, 4.43; N, 16.52%.

Compound 25e. Yield: 1.55 g (90%); mp 254-256 °C. IR: 3405 (OH); 3136 (NH); 1651 (CO); ¹H NMR: 13.35 (s, 1H, NH), 9.87 (s, 1H, OH), 9.48 (s, 1H, OH), 8.95 (s, 1H, CH, azomethine), 8.40 (s, 1H, CH, azomethine), 7.66 (br. s., 1H, aryl-H), 7.47-7.49 (d, 1H, aryl-H), 7.33 (br. s., 1H, Ar-H), 7.23 (m, 4H, aryl-H's), 7.12-7.15 (m, 2H, aryl-H's), 6.95-6.98 (m, 1H, aryl-H), 6.81-6.83 (m, 1H, aryl-H), 5.83 (s, 1H, C⁸H of cyclohexene ring), 4.34-4.38 (d, 1H,

C⁹H of cyclohexene ring), 4.03 (d, 1H, C⁹H of cyclohexene ring), 3.92 (s, 3H, OCH₃), 3.80 (s, 3H, OCH₃), 2.94 (s, 3H, CH₃) ppm. Anal. Calcd. For C₃₂H₂₈N₆O₅ (576.21): C, 66.66; H, 4.89; N, 14.58%. Found: C, 66.82; H, 4.73; N, 14.29%.

Compound 25f. Yield: 1.56 g (91%); mp 323-325 °C. IR: 3134 (NH); 1649 (CO). ¹H NMR: 13.75 (s, 1H, NH), 12.20 (s, 2H, two CH, azomethine), 8.29-8.57 m, 5H, aryl-H's), 7.98-8.00 (d, 2H, aryl-H's), 7.22-7.27 (m, 6H, aryl-H's), 5.91 (s, 1H, C⁸H of cyclohexene ring), 5.47 (s, 1H, C⁹H of cyclohexene ring), 4.00 (d, 1H, C⁹H of cyclohexene ring), 2.84 (s, 3H, CH₃) ppm. Anal. Calcd. For C₃₀H₂₂N₈O₅ (574.17): C, 62.71; H, 3.86; N, 19.50%. Found: C, 62.48; H, 3.93; N, 19.37%.

3-(4-Hydroxypent-3-en-2-ylidene)amino)-5,9,11-trimethyl-2-phenyl-2,3-dihydropyrimido[1',2':1,5]pyrazolo[3,4-c][2,7]naphthyridin-4(1H)-one (26). A mixture of **24** (0.92 g, 0.003 mol) acetylacetone (0.30 mL, 0.003 mol) in EtOH (20 mL) was refluxed for 4 h. The obtained solid was crystallized from dioxane to give pale yellow needles of **26**. Yield: 1.20 g (88%); mp 289-281°C. IR: 3269 (OH); 3030 (CH, arom.); 1668 (CO); 1626 (CN). ¹H NMR: 11.73 (s, 1H, OH), 7.21-7.28 (m, 5H, aryl-H,s), 7.06 (s, 1H, pyrimidine-H), 5.17 (s, 1H, C=CH), 5.12-5.14 (dd, 1H, CH), 4.43-4.48 (dd, 1H, CH), 4.43-4.48 (dd, 1H, CH), 4.17-4.22 (d, 1H, CH), 3.12 (s, 3H, CH₃), 2.92 (s, 3H, CH₃), 2.70 (s, 3H, CH₃), 2.69 (s, 3H, CH₃), 2.06 (s, 3H, CH₃), 1.96 (s, 3H, CH₃) ppm. ¹³C NMR and Dept 135: 197.01, 165.25, 164.59, 163.35, 159.80, 158.36, 146.27, 145.63, 144.40, 138.39, 129.06, 128.67 (CH), 128.33, 127.08 (CH), 126.59 (CH), 115.72, 113.32 (CH of pyrimidine ring), 101.66, 97.04 (=CH), 63.56 (CH, of cyclohexene ring), 32.57 (CH₂ of cyclohexene ring), 29.17 (CH₃), 27.80 (CH₃), 24.68 (CH₃), 18.21 (CH₃), 17.83 (CH₃) ppm. Anal. Calcd. For C₂₆H₂₆N₆O₂ (454.21): C, 68.70; H, 5.77; N, 18.49%. Found: C, 68.63; H, 6.02; N, 18.37%.

Acknowledgements

The authors extend their appreciation to Taif University, Saudi Arabia for supporting this work through Project Number (TU-DSPP-2024-150).

Supplementary Material

Copies of IR, ¹H NMR and ¹³C NMR and MS spectra of synthesized compounds are available in the supplementary material file associated with this manuscript.

References

- Alexopoulos, D. *Cardiology* **2014**, *127*, 211.
<https://doi.org/10.1159/000357399>
- Saito, K.; Shinozuka, T.; Nakao, A.; Kiho, T.; Kunikata, T.; Shiiki, T.; Nagai, Y.; Naito, S. *Bioorg. Med. Chem. Lett.* **2019**, *29*, 1769.
<https://doi.org/10.1016/j.bmcl.2019.05.014>
- Zhao, Y.; Li, M.; Li, B.; Zhang, S.; Su, A.; Xing, Y.; Ge, Z.; Li, R.; Yang, B. *Eur. J. Med. Chem.* **2019**, *172*, 131.
<https://doi.org/10.1016/j.ejmech.2019.03.060>

4. Wu, J.-P.; Fleck, R.; Brickwood, J.; Capolino, A.; Catron, K.; Chen, Z.; Cywin, C.; Emeigh, J.; Foerst, M.; Ginn, J.; Hrapchak, M.; Hickey, E.; Hao, M.-H.; Kashem, M. Li, J.; Liu, W.; Morwick, T.; Nelson, R.; Marshall, D.; Martin, L.; Nemoto, P.; Potocki, I.; Liuzzi, M.; Peet, G.W.; Scouten, E.; Stefany, D.; Turner, M.; Weldon, S.; Zimmitti, C.; Spero, D.; Kelly, T.A. *Bioorg. Med. Chem. Lett.* **2009**, *19* 5547.
<https://doi.org/10.1016/j.bmcl.2009.08.054>
5. Sleebs, B. E.; Levit, A.; Street, I. P.; Falk, H.; Hammonds, T.; Wong, A.C.; Charles, M.D.; Olson, M.F.; Baell, J.B. *Med. Chem. Commun.* **2011**, *2*, 977.
<https://doi.org/10.1039/c1md00137j>
6. Elgohary, A.M.F.; Ezz El Arab, E.M. *Sci. J. Chem.* **2013**, *1*, 1
7. Mousa, B. A.; Bayoumi, A. H.; Korraa1, M. M.; Assy, M. G.; El-Kalyoubi, S.. *Int. J. Org. Chem.* **2015**, *5*, 37.
<https://doi.org/10.4236/ijoc.2015.51005>
8. Barlin, G.; Tan, W. *Aust. J. Chem.* **1984**, *37*, 1065.
<https://doi.org/10.1071/CH9841065>
9. Dianzani, C.; Gallicchio, M.; Braccio, M. D.; Roma, G.; Fantozzi, R. *J. Inflamm. Res.* **2006**, *3*, Article number: 4
<https://doi.org/10.1186/1476-9255-3-4>
10. Kuroda, T.; Suzuki, F.; Tamura, T.; Ohmori, K.; Hosoe, H. *J. Med. Chem.* **1992**, *35*, 1130.
<https://doi.org/10.1021/jm00084a019>
11. Kuo, S.C.; Tsai, S.Y.; Li, H.-T.; Wu, C.-H.; Ishll, K.; Nakamura, H. *Chem. Pharm. Bull.* **1988**, *36*, 4403.
<https://doi.org/10.1248/cpb.36.4403>
12. Quintela, M.; Peinador, C.; González, L.; Iglesias, R.; Paramá, A.; Álvarez, F.; Sanmartín, M. L.; Riguera, R. *Eur. J. Med. Chem.* **2003**, *38*, 265
[https://doi.org/10.1016/S0223-5234\(03\)00032-1](https://doi.org/10.1016/S0223-5234(03)00032-1)
13. Hameed, S.; Madhavapeddi, P.; Menasinakai, S.; Sharma, S.; Kaur, P.; Nandishaiah, R.; Panduga, V.; Reddy, J.; Sambandamurthy, V. K.; Sriram, D. *ACS Med. Chem. Lett.* **2014**, *5*, 820.
<https://doi.org/10.1021/ml5001728>
14. Pietro, O. D.; Pérez-Areales, F. J.; Juárez-Jiménez, J.; Espargaró, A.; Clos, M. V.; Pérez, B.; Lavilla, R.; Sabaté, R.; Luque, R. J.; Muñoz-Torrero, D. *Eur. J. Med. Chem.* **2014**, *84*, 107.
<https://doi.org/10.1016/j.ejmech.2014.07.021>
15. Jansen, K.; Heirbaut, L.; Verkerk, R.; Cheng, J. D.; Joossens, J.; Cos, P.; Maes, L.; Lambeir, A.-M.; Meester, I. D.; Augustyns, K.; Veken, P. V. *J. Med. Chem.* **2014**, *57*, 3053.
<https://doi.org/10.1021/jm500031w>
16. Giacomello, G.; Gualtieri, F.; Riccieri, F.M.; Stein, M.L. *Tetrahedron Lett.* **1965**, *6*, 1117
[https://doi.org/10.1016/S0040-4039\(00\)90042-X](https://doi.org/10.1016/S0040-4039(00)90042-X)
17. Madaan, A.; Verma, R.; Kumar, V.; Singh, T.; Jain, S. K.; Jaggi, M. *Arch. Pharm.* **2015**, *348*, 837.
<https://doi.org/10.1002/ardp.201500237>
18. Gutham, K.; Kadiyala, V.; Sridhar, B.; Karunakar, G. V. *Org. Biomol. Chem.* **2017**, *15*, 7813.
<https://doi.org/10.1039/C7OB01285C>
19. Schmitz, F. J.; DeGuzman, F. S.; Hossain, M. B.; Vander-Helm, D. *J. Org. Chem.* **1991**, *56*, 804.
<https://doi.org/10.1021/jo00002a055>
20. Nittoli, T.; Dushin, R. G.; Ingalls, C.; Cheung, K.; Floyed, M. B.; Faser, H.; Olland, A.; Hu, Y.; Grosu, G.; Han, X. *Eur. J. Med. Chem.* **2010**, *45*, 1379
21. Al-Waleedy, S. A. H.; Bakhite, Etify A.; Abbady, M. S.; Abdu-Allah, H. H. M.; *J. Heterocycl. Chem.* **2020**, *57*, 2379.

22. Al-Taifi, E. A.; Al-Waleedy, S. A. H.; Abbady, M. S.; Abdu-Allah, H. H. M.; Marae, I. S.; Abuelhassan, S.; Bakhite, E. A. *Arkivoc* **2020**, (viii), 46.
<https://doi.org/10.24820/ark.5550190.p011.295>
23. EL-Mahdy, A. F. M.; Bakhite, E. A., Abdel-Hafez, S. H.; Ibrahim, O. F., Abdu-Allah, Hajjaj H. M.; Marae, I. S. *J. Heterocycl. Chem.* **2022**, 59, 359.
<https://doi.org/10.1002/jhet.4391>
24. Bakhite, E. A.; Abd-Ella, A. A.; El-Sayed, M. E. A.; Abdel-Raheem, S. A. A. *J. Saudi Chem. Soc.* **2017**, 21, 95-104.
<https://doi.org/10.1016/j.jscs.2016.02.005>

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)